Long-term high-flow hemoadsorption for dialysis patients
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a long-term, high-flow hemoadsorption therapy for people on maintenance hemodialysis. It aims to see if the treatment can improve outcomes for those with uremia (built-up waste in the blood).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently on maintenance hemodialysis (regular dialysis) and also receive hemoadsorption (HA) treatments.
- Your blood albumin level (a measure of nutrition) is above 30 g/L.
- Your platelet count (blood clotting cells) is between 40 and 300 (×10^9/L).
- You have no new heart or blood vessel problems (like a heart attack or stroke) recently.
- Your dialysis access (like a fistula or graft) works well enough to allow a blood flow of at least 250 ml per minute.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether adding a special blood-filtering treatment (hemoperfusion) to your regular hemodialysis can improve outcomes for people with end-stage kidney disease. It may be a good option if you have been on dialysis for a while and have little to no remaining kidney function.
This study tests a therapy that absorbs inflammatory substances from the blood during dialysis. It may help people on dialysis who have ongoing inflammation, shown by high IL-6 or CRP levels.
This trial tests a special dialysis filter (Elisio HX) that removes more waste products from the blood. It aims to see if this approach improves health outcomes for people on regular in-center hemodialysis.
This trial tests whether adding a special filter called pHA130 to your regular dialysis treatments can better remove certain waste products from your blood and improve your quality of life. It's for people who have been on dialysis for at least 3 months and meet a few health requirements.
This study tests a special filter called pHA130 that is used during your regular hemodialysis sessions for a full 4 hours. The purpose is to see if it helps improve your dialysis treatment outcomes.
This trial tests a special blood-filtering treatment (hemoperfusion) for people with advanced kidney disease on regular dialysis. It aims to remove harmful substances that standard dialysis may not fully clear.
Hear when a new Hemodialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.